Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

前列腺癌 医学 前列腺 癌症 阉割 肿瘤科 内科学 激素
作者
Silke Gillessen,Alberto Bossi,Ian D. Davis,Johann S. de Bono,Karim Fizazi,Nicholas D. James,Nicolas Mottet,Neal D. Shore,Eric J. Small,Matthew R. Smith,Christopher J. Sweeney,Bertrand Tombal,Emmanuel S. Antonarakis,Ana M. Aparicio,Andrew J. Armstrong,Gerhardt Attard,Tomasz M. Beer,Himisha Beltran,Anders Bjartell,Pierre Blanchard
出处
期刊:European Journal of Cancer [Elsevier BV]
卷期号:185: 178-215 被引量:114
标识
DOI:10.1016/j.ejca.2023.02.018
摘要

Background: Innovations in imaging and molecular characterisation together with novel treatment options have improved outcomes in advanced prostate cancer. However, we still lack high-level evidence in many areas relevant to making management decisions in daily clinical practise. The 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) addressed some questions in these areas to supplement guidelines that mostly are based on level 1 evidence. Objective: To present the voting results of the APCCC 2022. Design, setting, and participants: The experts voted on controversial questions where high-level evidence is mostly lacking: locally advanced prostate cancer; biochemical recurrence after local treatment; metastatic hormone-sensitive, non-metastatic, and metastatic castration-resistant prostate cancer; oligometastatic prostate cancer; and managing side effects of hormonal therapy. A panel of 105 international prostate cancer experts voted on the consensus questions. Outcome measurements and statistical analysis: The panel voted on 198 pre-defined questions, which were developed by 117 voting and non-voting panel members prior to the conference following a modified Delphi process. A total of 116 questions on metastatic and/or castration-resistant prostate cancer are discussed in this manuscript. In 2022, the voting was done by a web-based survey because of COVID-19 restrictions. Results and limitations: The voting reflects the expert opinion of these panellists and did not incorporate a standard literature review or formal meta-analysis. The answer options for the consensus questions received varying degrees of support from panellists, as reflected in this article and the detailed voting results are reported in the supplementary material. We report here on topics in metastatic, hormone-sensitive prostate cancer (mHSPC), non-metastatic, castration-resistant prostate cancer (nmCRPC), metastatic castration-resistant prostate cancer (mCRPC), and oligometastatic and oligoprogressive prostate cancer. Conclusions: These voting results in four specific areas from a panel of experts in advanced prostate cancer can help clinicians and patients navigate controversial areas of management for which high-level evidence is scant or conflicting and can help research funders and policy makers identify information gaps and consider what areas to explore further. However, diagnostic and treatment decisions always have to be individualised based on patient characteristics, including the extent and location of disease, prior treatment(s), co-morbidities, patient preferences, and treatment recommendations and should also incorporate current and emerging clinical evidence and logistic and economic factors. Enrolment in clinical trials is strongly encouraged. Importantly, APCCC 2022 once again identified important gaps where there is non-consensus and that merit evaluation in specifically designed trials. Patient summary: The Advanced Prostate Cancer Consensus Conference (APCCC) provides a forum to discuss and debate current diagnostic and treatment options for patients with advanced prostate cancer. The conference aims to share the knowledge of international experts in prostate cancer with healthcare providers worldwide. At each APCCC, an expert panel votes on pre-defined questions that target the most clinically relevant areas of advanced prostate cancer treatment for which there are gaps in knowledge. The results of the voting provide a practical guide to help clinicians discuss therapeutic options with patients and their relatives as part of shared and multidisciplinary decision-making. This report focuses on the advanced setting, covering metastatic hormone-sensitive prostate cancer and both non-metastatic and metastatic castration-resistant prostate cancer. Twitter summary: Report of the results of APCCC 2022 for the following topics: mHSPC, nmCRPC, mCRPC, and oligometastatic prostate cancer. Take-home message: At APCCC 2022, clinically important questions in the management of advanced prostate cancer management were identified and discussed, and experts voted on pre-defined consensus questions. The report of the results for metastatic and/or castration-resistant prostate cancer is summarised here.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
李妍发布了新的文献求助80
刚刚
小古完成签到,获得积分10
1秒前
PEACE发布了新的文献求助10
2秒前
2秒前
3秒前
3秒前
5秒前
fishss完成签到,获得积分0
6秒前
MADAO发布了新的文献求助30
6秒前
Nidhogg完成签到,获得积分20
7秒前
852的应助被俭朴钢铁侠采纳,获得10
7秒前
那地方完成签到,获得积分0
7秒前
小马甲的应助被等风归采纳,获得10
7秒前
小蜜蜂完成签到,获得积分10
7秒前
在水一方的应助被喝口可乐采纳,获得30
7秒前
LW3366发布了新的文献求助10
8秒前
马亚斌发布了新的文献求助10
8秒前
秋风的应助被芒果彩虹猪采纳,获得20
9秒前
GPTea的应助被jean采纳,获得20
9秒前
applennad完成签到,获得积分10
9秒前
10秒前
11秒前
11秒前
努力搬砖的小胡完成签到,获得积分10
12秒前
稳重的元瑶完成签到,获得积分10
12秒前
马亚斌完成签到,获得积分20
13秒前
瓦松完成签到,获得积分20
14秒前
等风归完成签到,获得积分10
14秒前
云朝完成签到,获得积分10
15秒前
16秒前
16秒前
ZeKaWa的应助被liu采纳,获得10
16秒前
PEACE完成签到 ,获得积分20
16秒前
儒雅黑猫完成签到 ,获得积分10
16秒前
17秒前
思恩Shen发布了新的文献求助10
17秒前
秦风完成签到,获得积分10
18秒前
杜欣悦发布了新的文献求助10
18秒前
香蕉觅云的应助被顺利毕业mpa采纳,获得10
18秒前
94完成签到,获得积分10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181839
求助须知:如何正确求助?哪些是违规求助? 9571584
关于积分的说明 21818707
捐赠科研通 7778124
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557710
邀请新用户注册赠送积分活动 2479621